ライフサイエンスコーパス: keratoconus

1 Fifty eyes of 50 participants with keratoconus.

2 fter PK, occurred among the 56 patients with keratoconus.

3 ct long-term corneal status in patients with keratoconus.

4 orneal cross-linking is widely used to treat keratoconus.

5 achieved in eyes with progressive, advanced keratoconus.

6 AS-OCT confirmed the diagnosis of posterior keratoconus.

7 corneal densitometry after CXL and CRXL for keratoconus.

8 s not been previously described in posterior keratoconus.

9 sepithelial CXL for treatment of progressive keratoconus.

10 for some patients to halt the progression of keratoconus.

11 orneal collagen cross-linking in progressive keratoconus.

12 index showed 78% sensitivity for subclinical keratoconus.

13 Corneal hysteresis after CXL for keratoconus.

14 69 predispose to the development of isolated keratoconus.

15 oach to reduce ectasia in eyes with advanced keratoconus.

16 t DALK or penetrating keratoplasty (PKP) for keratoconus.

17 ociated with the pathological progression of keratoconus.

18 es of 95 patients with moderate and advanced keratoconus.

19 le efficacy profile in moderate and advanced keratoconus.

20 eived significant attention for treatment of keratoconus.

21 tions and stabilize corneas with progressive keratoconus.

22 ratoconus, and 148 eyes of 102 patients with keratoconus.

23 play a role in the thinning associated with keratoconus.

24 chymetry values but no pattern indicative of keratoconus.

25 t only temporary results in the treatment of keratoconus.

26 ments compared with ultrasound pachymetry in keratoconus.

27 e expected in patients with a milder form of keratoconus.

28 ollowing ICRS implantation for correction of keratoconus.

29 ed in vivo to the cornea in the treatment of keratoconus.

30 ion, is a potential susceptibility locus for keratoconus.

31 included, especially in cases of subclinical keratoconus.

32 sensitivity in the diagnosis of subclinical keratoconus.

33 ys after ICRS implantation for correction of keratoconus.

34 riboflavin is a promising new treatment for keratoconus.

35 in patients with postrefractive ectasia than keratoconus.

36 to increased susceptibility to developing of keratoconus.

37 o be impaired by a high degree of myopia and keratoconus.

38 reatment targeting the stroma in progressive keratoconus.

39 d, including primary open-angle glaucoma and keratoconus.

40 and/or topographic features consistent with keratoconus.

41 tion may have a particular susceptibility to keratoconus.

42 gy practice and examined for the presence of keratoconus.

43 a role in the development and progression of keratoconus.

44 ay provide information on the progression of keratoconus.

45 ease, which is typically called forme fruste keratoconus.

46 s safe and moderately effective for advanced keratoconus.

47 the conventional protocol to treat pediatric keratoconus.

48 e rates of scleral lens correction in severe keratoconus.

49 e was the annual incidence and prevalence of keratoconus.

50 s obtained using 3 tomographers in eyes with keratoconus.

51 the corneal stroma of patients with advanced keratoconus.

52 e for the cost-effectiveness of early CXL in keratoconus.

53 onal management with PKP in the treatment of keratoconus.

54 ccess of the toric IOL implantation, even in keratoconus.

55 nking (CXL) for the treatment of progressive keratoconus.

56 y at a tertiary eye care center for advanced keratoconus.

57 d healing after epi-off CXL in patients with keratoconus.

58 oor visual outcomes after big-bubble DALK in keratoconus.

59 s-linking (CXL) in patients with progressive keratoconus.

60 eal wound healing after CXL in patients with keratoconus.

61 lue, CDVA, and UCVA in eyes with progressive keratoconus 1 year after treatment, with an excellent sa

62 tandard CL) for the treatment of progressive keratoconus 12 months after the operation.

63 %), anterior segment dysgenesis (15.2%), and keratoconus (14.3%).

64 edema mostly affecting elderly individuals; keratoconus (27%), a corneal disease that slowly deforms

65 patients; using Krumeich's classification of keratoconus, 3 eyes were found to be at stage 1, 3 at st

66 3.7+/-5.9 years) than patients with no acute keratoconus (32.7+/-11.3 years).

67 n abnormal eyes, 92.8% to 95.0% in eyes with keratoconus, 75.2% to 92.0% in eyes with subclinical ker

68 ge of 7.82 +/- 4.64 years underwent DALK for keratoconus (8), microbial keratitis (6), corneal scar (

69 Keratoconus, a common inherited ocular disorder resultin

70 utcome measure was clinical stabilization of keratoconus after 1 year, defined as a maximal keratomet

71 primary outcome measure was stabilization of keratoconus after 12 months through analysis of maximum

72 These were three affected brothers, one with keratoconus, all with CRB1 mutations.

73 ot improve vision in patients with stage 3-4 keratoconus (Amsler-Krumeich classification), but newer

74 re 18 to 28 years of age and had progressive keratoconus and a plan to be treated with CXL at Umea Un

75 l with epithelial off CXL, if diagnosed with keratoconus and a progression in Kmax of more than one d

76 includes a mildly reduced corneal thickness, keratoconus and blue sclera.

77 yes of 9 patients with progressive, advanced keratoconus and contact lens intolerance underwent the p

78 n in two independent panels of patients with keratoconus and controls and in keratoconus families.

79 (CXL) is designed to halt the progression of keratoconus and corneal ectasia by inducing corneal stif

80 9 eyes) aged 18 to 28 years with progressive keratoconus and corresponding age- and sex-matched healt

81 ion resulted in comparable representation of keratoconus and ectasia after refractive surgery in the

82 ty and sensitivity in discriminating between keratoconus and healthy eyes.

83 method for modifying the natural history of keratoconus and other corneal ectatic diseases.

84 ttractive approach to inhibit progression of keratoconus and other ectatic disorders.

85 orneal collagen is an evolving treatment for keratoconus and other ectatic disorders.

86 (UVA) is a promising and novel treatment for keratoconus and other ectatic disorders.

87 e for visual rehabilitation in children with keratoconus and poor CDVA.

88 d pediatric patients (aged </=14 years) with keratoconus and poor corrected distance visual acuity (C

89 own to be effective in the treatment of both keratoconus and post-LASIK ectasia.

90 and keratometric parameters in patients with keratoconus and postlaser in-situ keratomileusis ectasia

91 zation and to a lesser extent, regression of keratoconus and postrefractive surgery ectasia.

92 factor for various ocular diseases, such as keratoconus and primary open angle glaucoma.

93 ing or reversing progressive ectasia in both keratoconus and progressive post-LASIK keratectasia by m

94 s armamentarium for treatment of progressive keratoconus and progressive post-LASIK keratectasia.

95 s as well as in the treatment of progressive keratoconus and progressive postlaser in-situ keratomile

96 ting between normal corneas and forme fruste keratoconus and provided a tool that is closer to an aut

97 uld be used as topical stiffening agents for keratoconus and related disorders.

98 been shown to be an effective treatment for keratoconus and related keratectasias.

99 which were from patients affected by severe keratoconus and submitted to penetrating keratoplasty (P

100 he relevant age category for newly diagnosed keratoconus and the annual incidence of newly diagnosed

101 so provides insight into the pathogenesis of keratoconus and treatment strategies for future research

102 ts, 47 eyes of 47 patients with forme fruste keratoconus, and 148 eyes of 102 patients with keratocon

103 nus, 75.2% to 92.0% in eyes with subclinical keratoconus, and 93.1% to 97.2% in normal eyes.

104 r penetrating grafts are being performed for keratoconus, and more endokeratoplasties but fewer penet

105 l eyes, eyes with keratoconus or subclinical keratoconus, and normal eyes.

106 nd understanding the roles of these genes in keratoconus are warranted.

107 ling corneal shape and in the development of keratoconus, astigmatism, and other refractive errors.

108 rameters were strong enough to differentiate keratoconus (AUC > 0.9).

109 d on 40 eyes of 32 patients with progressive keratoconus between 2006 and 2012.

110 nducted in the National Reference Center for Keratoconus, Bordeaux (France), between October 1997 and

111 allows structural follow-up of patients with keratoconus but also provides insight into the pathogene

112 me two SNPs were found to be associated with keratoconus by family-based association testing with P v

113 or some indices and up to 10% of subclinical keratoconus cases may go undetected by this technology.

114 Data collected from patients with advanced keratoconus cases were studied during a minimum period o

115 toconic eyes from 191 patients with advanced keratoconus cases were studied.

116 pflug tomography can detect most subclinical keratoconus cases with unremarkable topography, but perf

117 ography (n = 37) were considered subclinical keratoconus cases.

118 A discovery panel of 222 keratoconus Caucasian patients and 3324 Caucasian contro

119 l keratocytes (HCKs), fibroblasts (HCFs) and keratoconus cells (HKCs).

120 Human corneal fibroblasts(HCFs) and human keratoconus cells(HKCs) were treated with a stable Vitam

121 A total of 126 patients from the keratoconus center of Homburg/Saar were evaluated with r

122 s an incompletely understood complication of keratoconus, characterized by marked corneal edema cause

123 entacam (Keratoconus Index [KI], Topographic Keratoconus Classification [TKC]), Topographic Modeling

124 the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study used 7 years of follow-up data

125 d patients with keratoconus who attended the keratoconus clinic at the Antwerp University Hospital, B

126 a P values of rs1536482 and rs7044529 in the keratoconus cohorts were 1.5 x 10(-4) (odds ratio [OR] =

127 (MIR184) is responsible for familial severe keratoconus combined with early-onset anterior polar cat

128 ere observed in the corneas of patients with keratoconus compared with healthy corneas.

129 Several anatomic features at the keratoconus cone were analyzed with OCT, including epith

130 ithelial thickening, stromal thinning at the keratoconus cone, anterior hyperreflectives at the Bowma

131 3 high-resolution scans were made across the keratoconus cone.

132 iopters (D) from baseline to 1 year, whereas keratoconus continued to progress in the control group.

133 Genetic associations for keratoconus could be useful for understanding disease pa

134 alPower index was calculated to stratify the keratoconus data from mild to severe.

135 After diagnosis, keratoconus did not evolve more frequently in children.

136 ar and within COL5A1) were identified in the keratoconus discovery cohort (P values of 6.5 x 10(-3) a

137 ndications for PK between 1980 and 2014 were keratoconus (Europe, Australia, the Middle East, Africa,

138 However, in the case of progression, keratoconus evolved faster in children, with significant

139 alues for every index, whereas 7 subclinical keratoconus eyes (19%) showed 2 or fewer abnormal indice

140 ccount by the clinician in the evaluation of keratoconus eyes and in the planning of corneal keratopl

141 In forme fruste keratoconus eyes, the ART max is considered a highly sen

142 In the clinical keratoconus eyes, the mean K, back difference elevation

143 ssessment of structural changes occurring in keratoconus eyes.

144 A genomewide linkage scan in keratoconus families identified a locus at 5q23.2, overl

145 two independent case-control samples and in keratoconus families.

146 atients with keratoconus and controls and in keratoconus families.

147 0.02), and SNP rs7044529 was replicated in a keratoconus family panel (P = 0.03).

148 lasts (HCFs) from healthy patients and Human Keratoconus fibroblasts (HKCs) from KC patients.

149 gular corneal astigmatism and a patient with keratoconus following pars plana vitrectomy.

150 ogistic regression model that best separates keratoconus from normal and was applied to all data sets

151 all 3 machines can effectively differentiate keratoconus from normal corneas.

152 collagen crosslinking (CXL) for progressive keratoconus from the healthcare payer's perspective.

153 ceiving a first penetrating keratoplasty for keratoconus, Fuchs' endothelial disease, or pseudophakic

154 -RMS, PosICP-RMS and CM were correlated with keratoconus grade (p < 0.05).

155 ween Groups 1 and 2 and were correlated with keratoconus grade.

156 t significant genetic factor responsible for keratoconus identified to date.

157 eratoplasty (PKP) when indicated in managing keratoconus in Canada.

158 in LOX transcripts I and II, associated with keratoconus in case-control and family samples with a me

159 Keratoconus in children was significantly more severe at

160 utic modality for the management of advanced keratoconus in children.

161 ratoplasty: 4 had granular dystrophy, 12 had keratoconus in its final stages, 3 had post-herpetic leu

162 A total of 48 patients with clinical keratoconus in one eye and forme fruste keratoconus in t

163 Patients with clinical keratoconus in one eye and forme fruste keratoconus in t

164 ical keratoconus in one eye and forme fruste keratoconus in the fellow eye and 72normal subjects were

165 ical keratoconus in one eye and forme fruste keratoconus in the fellow eye were compared to subjects

166 : 11.6-15.2) and the estimated prevalence of keratoconus in the general population was 1:375 (265 cas

167 t or pathologic nerve morphology persists in keratoconus in the long term after corneal collagen cros

168 the age-specific incidence and prevalence of keratoconus in the modern era of diagnostics.

169 previous scleral buckling in one case and by keratoconus in the other case.

170 ide polymorphisms (SNPs) in 6 genes/loci for keratoconus in Whites.

171 Clinical and paraclinical characteristics of keratoconus, including visual acuity, corneal epithelium

172 Optimized cutoff values for subclinical keratoconus increased the sensitivity of the standardize

173 5), index of surface variance (P < .05), and keratoconus index (P = .008) and decline in central corn

174 eratoconus index (P = 0.03), and the central keratoconus index (P = 0.016) were reduced significantly

175 index of vertical asymmetry (P = 0.04), the keratoconus index (P = 0.03), and the central keratoconu

176 respect to Amsler criteria, using Pentacam (Keratoconus Index [KI], Topographic Keratoconus Classifi

177 tional study of 19 patients with early-stage keratoconus indicated for a first CXL treatment with lon

178 We derived thresholds for the metric keratoconus indices KI and KMI, which allow classificati

179 Keratoconus indices measured by all 3 machines can effec

180 Keratoconus is a bilateral noninflammatory progressive c

181 Keratoconus is a condition in which the cornea progressi

182 Posterior keratoconus is a rare cause of a corneal opacity in an i

183 ctive management of acute corneal hydrops in keratoconus is based on recognizing and addressing the r

184 Keratoconus is characterized by a neurotrophic deficit a

185 orneal collagen crosslinking for progressive keratoconus is cost effective at a willingness-to-pay th

186 ns intolerant patients with mild to moderate keratoconus is increasingly gaining acceptance in the op

187 At diagnosis, keratoconus is often more advanced in children than in a

188 Keratoconus (KC) affects 1:2000 people and is a disorder

189 nd regulation of beta-actin in the stroma of keratoconus (KC) and normal corneas.

190 hy in successive measurements by Pentacam in keratoconus (KC) and normal eyes based on the Iterative

191 nclear whether the oxidative damage found in keratoconus (KC) corneas results from innate defects of

192 Keratoconus (KC) is a corneal thinning disease with an o

193 Keratoconus (KC) is a corneal thinning disorder that lea

194 Keratoconus (KC) is usually a bilateral corneal ectatic

195 tomography for the detection of sub-clinical keratoconus (KC) with a Zernike application method.

196 had undergone a first corneal transplant for keratoconus (KC), Fuchs endothelial dystrophy (FED), pse

197 ting metabolism and inflammatory pathways in Keratoconus (KC), which is a corneal thinning disease as

198 d corneal cross-linking (A-CXL) in pediatric keratoconus (KC).

199 by UHR-OCT in the diagnosis of sub-clinical keratoconus (KC).

200 ed as forme fruste (FFKc, n = 212) and overt keratoconus (Kc, n = 222).

201 Keratoconus(KC) is an ecstatic corneal disease leading t

202 emic diseases, sociodemographic factors, and keratoconus (KCN) among a large, diverse group of insure

203 Keratoconus (KTCN) is a noninflammatory thinning and ant

204 alyzer (Keratoconus Match Probability [KMP], Keratoconus Match Index [KMI]).

205 Klyce/Maeda), and Ocular Response Analyzer (Keratoconus Match Probability [KMP], Keratoconus Match I

206 us Descemet s (basement) membrane rupture in keratoconus, mimicking this animal model and highlightin

207 Patients with progressive keratoconus (n = 205).

208 IOL implantation in a vitrectomized eye with keratoconus nor of toric IOL implantation in patients wi

209 If CXL had a stabilizing effect on keratoconus of 15 years or longer, then the ICER would b

210 hree subjects with the CRX mutation, one had keratoconus, one had the keratoglobus-like presentation,

211 sion from VKC-induced corneal astigmatism or keratoconus, only 1 child was visually impaired in both

212 Patients with progressive keratoconus or ectasia after refractive surgery (n = 510

213 Irregular corneal astigmatism in keratoconus or scleral-buckle-induced regular astigmatis

214 iscriminating among abnormal eyes, eyes with keratoconus or subclinical keratoconus, and normal eyes.

215 Keratoconus, suspected keratoconus, or its absence were determined in each pati

216 g penetrating grafts and DALKs performed for keratoconus over the same era, both graft survival (P <0

217 in ZNF469 associated with the development of keratoconus (P = 0.00102) resulting in a relative risk o

218 his study included all consecutively treated keratoconus patients (102 eyes) in 1 academic treatment

219 A Caucasian case-control cohort of 222 keratoconus patients and 3324 controls was selected as t

220 Sequencing of LOX exons in a subset of keratoconus patients identified two polymorphisms, rs180

221 neous tPRK followed by CXL in this series of keratoconus patients offered significantly improved visi

222 lly pathogenic alleles in ZNF469 in 12.5% of keratoconus patients represents a significant mutational

223 Twenty-nine keratoconus patients were randomized in three trial cent

224 Keratoconus patients with an elongated posterior segment

225 ation followed by cross-linking in pediatric keratoconus patients.

226 ive in slowing or halting the progression of keratoconus, pellucid marginal degeneration, and post-LA

227 RFUVA treatment retards the progression of keratoconus, perhaps by cross-linking of collagen molecu

228 neal scarring or infiltrates in children are keratoconus, phlyctenulosis, and herpes simplex keratiti

229 for keratoplasty was more than halved in our keratoconus population.

230 tion therapy has shown promising results for keratoconus, post-LASIK ectasia, and pellucid marginal d

231 ique to reduce ectasia in eyes with advanced keratoconus, potentially allowing continued long-term co

232 am were statistically similar to that of the keratoconus prediction index (KPI) and keratoconus proba

233 f the keratoconus prediction index (KPI) and keratoconus probability (Kprob) of Galilei (P = .27) and

234 ng problems, 23% of cases showed a continued keratoconus progression after 1 year.

235 ion models to reflect the natural history of keratoconus progression and the impact of conventional m

236 mechanism whereby RFUVA cross-linking stops keratoconus progression has been achieved.

237 and HuGENET databases for genetic studies of keratoconus published from 1950 to June 2016.

238 had 73% and 89% sensitivity for subclinical keratoconus, respectively.

239 Keratoconus screening indices were evaluated using the P

240 Recipient age, keratoconus severity, donor-related variables, recipient

241 All scans were analyzed by keratoconus specialists who were not given access to pat

242 Groups were matched in terms of age and keratoconus stage.

243 For separation of keratoconus stages 0/1/2/3/4 we derived the following op

244 ain OCT classification containing 5 distinct keratoconus stages is proposed.

245 es KI and KMI, which allow classification of keratoconus stages.

246 discriminating between healthy (stage 0) and keratoconus (stages 2-4) eyes in comparison with the oth

247 ing family linkage analysis, we identified a keratoconus susceptibility locus at 9q34.

248 ify the available data and to identify a new keratoconus susceptibility locus.

249 To identify keratoconus susceptibility regions, we performed a compr

250 sociation study between COL5A1 variation and keratoconus susceptibility.

251 cate that one or more loci may contribute to keratoconus susceptibility.

252 Keratoconus, suspected keratoconus, or its absence were

253 rneal cross-linking (CXL) is a treatment for keratoconus that eliminates the need for keratoplasty in

254 Forty patients (44 eyes) with keratoconus that had serial evaluation for CCT, followin

255 Forty of the 51 eyes with severe keratoconus that would otherwise have undergone transpla

256 In case 5 (keratoconus), the OCT showed the achieved big-bubble and

257 For subclinical keratoconus, the highest sensitivity (100%) was seen for

258 se of CXL in the management of patients with keratoconus, the progression of abnormal innervation aft

259 these families and localize a novel gene for keratoconus to a 5.6-Mb interval on 13q32.

260 Given the large-scale use of CXL in modern keratoconus treatment, a tool with this capacity has a g

261 zed clinical trial enrolled 40 patients with keratoconus undergoing epi-off CXL from July 18, 2014, t

262 aly, 17 eyes of 17 patients with progressive keratoconus underwent confocal microscopy examination be

263 y, 138 eyes of 138 patients with progressive keratoconus underwent corneal collagen cross-linking (CX

264 The patients with keratoconus underwent standard epithelial-off UV-A/ribof

265 The annual incidence of keratoconus was 1:7500 in the relevant age category (13.

266 Mean (SD) age of the 19 patients with keratoconus was 27.5 (7.1) years (range, 19-44 years), a

267 normalities were more common indications and keratoconus was a less common indication for surgery in

268 Keratoconus was characterized by apical epithelial thinn

269 and the annual incidence of newly diagnosed keratoconus was determined.

270 The prevalence of keratoconus was estimated based on the annual incidence,

271 ween the control group and the patients with keratoconus was found at baseline, both with an applanat

272 in the corneas of patients with stage 1 or 2 keratoconus was reduced 51% (mean difference, 10.7 mm/mm

273 Highest sensitivity (100%) to diagnose keratoconus was seen for 6 parameters on Pentacam and 1

274 Keratoconus was the leading indication in Europe (24.2%)

275 a genetic determinant of the pathogenesis of keratoconus, we analyzed association results of LOX poly

276 h the annual incidence and the prevalence of keratoconus were 5-fold to 10-fold higher than previousl

277 eventeen patients (34 eyes) with progressive keratoconus were assigned to 2 groups: the worse eye (17

278 eventeen patients (18 eyes) with progressive keratoconus were enrolled.

279 rty-four patients (38 eyes) with progressive keratoconus were enrolled.

280 araclinical characteristics of patients with keratoconus were evaluated.

281 eal cross-linking for halting progression of keratoconus were investigated in a prospective, randomiz

282 our eyes of 25 participants with progressive keratoconus were randomized into T-ionto CL (22 eyes) or

283 One hundred eyes with progressive keratoconus were randomized into the CXL treatment or co

284 Thirty-one eyes with keratoconus were treated with an accelerated protocol (1

285 patients with documented progressive primary keratoconus were treated with customized CXL (n = 20) or

286 virtual patients with progressive bilateral keratoconus, were modeled; one cohort underwent CXL and

287 ly, collagen fibers appeared disorganized in keratoconus, while their pattern appears to be close to

288 Study population comprised patients with keratoconus who attended the keratoconus clinic at the A

289 imulated cohorts of 100 000 individuals with keratoconus who entered each treatment arm at 25 years o

290 , pseudophakic bullous keratopathy (PBK), or keratoconus who had undergone a penetrating keratoplasty

291 ed 194 consecutive eyes of 181 patients with keratoconus who underwent DALK using the big-bubble tech

292 s study included 36 eyes in 36 patients with keratoconus who underwent DALK using the big-bubble tech

293 Patients with clinical diagnosis of keratoconus who were contact lens intolerant and whose c

294 llowed for discrimination between normal and keratoconus with 100% sensitivity and 99.5% specificity,

295 ificity, and between normal and forme fruste keratoconus with 93.6% sensitivity and 97.2% specificity

296 lar pressure was identified in patients with keratoconus with any method, except for an increase at 1

297 our 5-year results, treatment of progressive keratoconus with CXL can stop disease progression, witho

298 ctors for predicting the outcome of treating keratoconus with CXL.

299 A total of 245 eyes underwent PK for keratoconus with mean follow-up of 5.6 +/- 3.6 years.

300 al of 158 eyes/150 consecutive patients with keratoconus with postoperative follow-up time equal to o